BLAINJECTIONINJECTABLE
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEMGLEE is a biosimilar insulin glargine developed by Viatris, designed to treat diabetes mellitus in patients requiring insulin therapy. It is a long-acting basal insulin analog that mimics endogenous insulin to regulate blood glucose levels. This is a follow-on biologic referencing the innovator insulin glargine products.
Peak
Peak lifecycle stage suggests stable market position with established sales infrastructure and moderate team sizing.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SEMGLEE offers experience in biosimilar commercialization, managed care negotiations, and established market dynamics. Career growth is tied to market share gains in a competitive insulin category and Viatris's broader diabetes franchise strategy.
Brand ManagerField Sales Representative
Worked on SEMGLEE at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.